The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
David P. Kodack(Novartis (United States)), Rakesh K. Jain(Massachusetts General Hospital), Divya Bezwada(Children's Medical Center), Ram C. Shankaraiah(University of Ferrara), Jonas Kloepper(Massachusetts General Hospital), Carey K. Anders(Duke University), Robert Schlegel(Pathways Behavioral Services), Melinda E. Sanders(Vanderbilt University), Dai Fukumura(Massachusetts General Hospital), Jantima Tanboon(Siriraj Hospital), Vasileios Askoxylakis(Servier (France)), Christina S.F. Wong(Western University), Shom Goel(Dana-Farber Cancer Institute), Dan G. Duda(Harvard University), Zheng Cao(Hubei University of Medicine), C. Ryan Miller(University of North Carolina at Chapel Hill), Jeffrey A. Engelman(Cancer Research Center), Carlotta Costa(Massachusetts General Hospital), Carlos L. Arteaga(The University of Texas Southwestern Medical Center), Alan Huang(Tango Therapeutics (United States)), Qing Sheng(Zhejiang Sci-Tech University), Gino B. Ferraro(Massachusetts General Hospital), Kamila Naxerova(Harvard University), Elena F. Brachtel(University of Miami Hospital), Rakesh R. Ramjiawan(Harvard University), Rita Das(Harvard University), Yongchul Song(Center for Cancer Research), Angela Tam(University College London), Bhushankumar Patel(Massachusetts General Hospital), Marni B. Siegel(University of North Carolina at Chapel Hill), Mónica V. Estrada(Vanderbilt University), Mark Badeaux(The University of Texas MD Anderson Cancer Center), Xiaolong Qi(Zhongda Hospital Southeast University)
Cited by 113
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k